Krishna Udayakumar MD, MBA

krishna

Core Faculty

Krishna Udayakumar, MD, MBA

Contact

ku@duke.edu

Degrees

MD, Duke University

MBA, Duke University

Dr. Krishna Udayakumar leads multiple initiatives at Duke in the fields of health innovation and globalization of healthcare. He is the founding Director of the Duke Global Health Innovation Center, focused on generating deeper evidence and support for the study, scaling, and adaptation of health innovations and policy reforms globally.  He is also Executive Director of Innovations in Healthcare, a non-profit co-founded by Duke, McKinsey & Company, and the World Economic Forum, leading the organization’s work to curate and scale the impact of transformative health solutions globally.

As Head of Global Innovation for Duke Health, Dr. Udayakumar is responsible for the development and implementation of global strategy as well as global business development for Duke Health, across healthcare delivery, biomedical sciences research, and health professions education and training.

At Duke University, Dr. Udayakumar holds the rank of Associate Professor of Global Health and Medicine, and is Associate Professor at Duke-NUS Medical School Singapore. His work has been published in leading academic journals such as the New England Journal of MedicineHealth Affairs, and Academic Medicine.

Born in Bangalore, India, Dr. Udayakumar spent his childhood in Virginia, and is a Phi Beta Kappa graduate of the University of Virginia, with a bachelor’s degree in interdisciplinary studies with distinction. He received both an MD and an MBA (with a concentration in Health Sector Management) from Duke University, where he was a Fuqua Scholar. Dr. Udayakumar completed his residency training in internal medicine at Duke and served as Assistant Chief Resident at the Durham VA Medical Center before joining the faculty of Duke University.

Kaye DR, Lee H-J, Gordee A, George DJ, Ubel PA, Scales CD, et al. Medication Payments by Insurers and Patients for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. JCO Oncol Pract. 2023 Apr;19(4):e600–17.

Dzimitrowicz HE, Wilson LE, Jackson BE, Spees LP, Baggett CD, Greiner MA, et al. End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy. JCO oncology practice. 2023 Feb;19(2):e213–27.

Dinan MA, Wilson LE, Greiner MA, Spees LP, Pritchard JE, Zhang T, et al. Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC). Urology. 2022 Oct;168:129–36.